Latest Technology Acquisitions News

Nanoveu’s half-year report reveals a sharp drop in revenue and a widening net loss, offset by key technological milestones including a 16nm AI chip tape-out, drone efficiency gains, and a strategic robotics acquisition.

TALi Digital is acquiring Datasphere Analytics to access cutting-edge memristive in-memory computing technology, aiming to enhance its AI-driven education platform. The company is concurrently raising $3.3 million to fund this strategic move and ongoing operations.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

RooLife Group (ASX:RLG) is expanding its renewable energy footprint by acquiring a battery storage and microgrid business and raising $1.06 million in a placement to fund growth and project delivery.

Smart Parking (ASX:SPZ) has acquired American Parking, adding 54 sites across Oklahoma, Texas, and Arkansas and boosting its US portfolio to over 200 locations. The $12 million deal is expected to be earnings accretive and supports the rollout of SmartCloud technology.

Tasmea Limited is set to acquire JPS Group for up to A$75 million, securing a foothold in Australia’s growing LNG and energy infrastructure sectors with a Tier-1 client base and a unique tech-enabled isolation technology.

InVert Graphite (ASX:IVG) is set to acquire RapidGraphite Pty Ltd, gaining exclusive rights to Curtin University’s RapidPulseTM graphite processing technology that promises rapid, acid-free conversion of natural graphite to battery-grade quality. Backed by positive test results and a A$2.5 million capital raise, this move aims to vertically integrate InVert’s Morogoro graphite project with cutting-edge processing innovation.

Web Travel Group (ASX:WEB) reported a standout FY26, driven by its WebBeds B2B platform’s 20% TTV growth and 24% EBITDA increase, while redeeming $250 million convertible notes and releasing its inaugural climate-focused Sustainability Report.

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.